Gain detailed insights into the trading activity of Congress members for Bruker on our government trades page. Stay updated on how elected officials are investing in BRKR.

Bruker - Government Trades

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

stock-1863880

News

BRKR

Bruker shares are trading lower by 6.6% during Thursday&#39;s session. The company announced a public offering of 6 million shares of its common stock.

Why Bruker (BRKR) Shares Are Falling During Thursday&#39;s Session

Worst Performing

BBVA

DASH

GEHC

MSTR

SBUX

SMCI

STLA

SWKS

15 large-cap stocks had a rough week, with CVS, Starbucks, and DoorDash all taking major hits. Analysts have lowered price targets on many.

Last Week&#39;s Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)

Red,Stock,Market,Price,Showing,Trader,Phobia,Of,Crisis,War

Movers

ANET

ASML

COIN

JBHT

TSLA

Last week&#39;s worst performers included Arm Holdings, Coinbase Global, Live Nation Entertainment and J.B. Hunt Transport Services.

Last Week&#39;s Worst-Performing Stocks: Are These 11 Large-Cap Stocks In Your Portfolio? (April 14-20, 2024)

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BIIB

CRWD

DENN

KALV

SHOP

SSNC

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday

Penny Stocks

Intraday Update

ARBB

ASPN

ATCH

BDRX

BGLC

Brighthouse Financial, Inc. - Common Stock

BIOL

BLKB

CDNS

CHSN

DBGI

DHAI

EXAI

EXPR

FAMI

FREE

GTHX

IPGP

JBLU

LIAN

Larimar Therapeutics, Inc. - Common Stock

LRMR

MGIH

NSTG

PLCE

RENB

RNLX

SBFM

SIEN

SPWR

SSRM

TRIP

TWOU

VCIG

VGAS

ZJYL

Shares of  IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.

Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

KRRO

MANU

MEDP

METC

PROC

VALU

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday.

Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday

Government

Health Care

General

TSX:CEMI

CODX

EXAS

TSX:FLDM

HOLX

Laboratory Corporation Of America Holdings

LMDX

OSUR

QDEL

QGEN

RHHBF

RHHBY

RHHVF

TWST

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

CELL

Bruker Corporation (NASDAQ: BRKR) has agreed to acquire PhenomeX Inc (NASDAQ: CELL) for $1.00 per share in an 

Bruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX Acquisition

Bull,And,Bear,Are,On,A,Graphic,With,Market,Prices.

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Currency ETFs

Economics

Federal Reserve

Tech

ETFs

BBDO

SPDR Dow Jones Industrial Average ETF Trust

PARAA

SIRI

SNAP

PowerShares DB US Dollar Index Bullish Fund

The Fed&#39;s Influence Ripples Through US Stocks, ETFs: Wednesday&#39;s Winners And Losers Revealed

CEMI

LHDX

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests

Bruker Corp

Based on cellular biophysical markers attained using Bruker&#39;s advanced atomic force microscopy, Cellens is developing its platform for detecting bladder cancer using voided urine samples from cancer patients. The technology has shown outstanding sensitivity and specificity in pilot clinical studies.&nbsp;

Contracts

Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning

At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025944&amp;newsitemid=20240603327426&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=a41daa44ad725e00e7727bb1f19c2f3e">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the&nbsp;neofleX Imaging Profiler&nbsp;for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new&nbsp;SCiLS Scope&nbsp;software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top.
&nbsp;
&nbsp;
At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025943&amp;newsitemid=20240603348539&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=2ceaf04d6f4b7914d0d2992ddf373d95">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) launches the new top-of-the-line&nbsp;timsTOF Ultra 2&nbsp;system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new&nbsp;Spectronaut 19software and the novel PreOmics&nbsp;ENRICHplus&nbsp;kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics. Bruker is also introducing&nbsp;OmniScape&nbsp;software for top-down sequence confirmation and&nbsp;de novo&nbsp;sequencing for intact, undigested proteoforms, dissociated in the mass spectrometer.

Bruker Launches NeofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications, TimsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares are trading lower by 6.6% to $67.80 during Thursday&#8217;s session after the company announced a public offering of 6 million shares of its <a href="https://www.benzinga.com/pressreleases/24/05/b39076707/bruker-announces-pricing-of-public-offering-of-common-stock">common stock</a>.
The offering comes with an option for underwriters to purchase an additional 900,000 shares within 30 days. The offering is set to close around May 31, pending customary conditions. The proceeds will be used to reduce debt from recent strategic acquisitions, including repaying part of its revolving credit agreement. 
BofA Securities and J.P. Morgan are managing the offering, and the shares will be available on the Nasdaq Global Select Market and other venues at prevailing or negotiated prices.
See Also: <a href="https://www.benzinga.com/markets/equities/24/05/39085465/us-q1-economic-growth-downwardly-revised-to-1-3-consumer-spending-falters">US Q1 Economic Growth Downwardly Revised To 1.3%: Consumer Spending Falters</a>
<h2 class="wp-block-heading">Should I Sell My BRKR Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Bruker have decreased by 5.73% in the past year. An investor who bought shares of Bruker at the beginning of the year would take a loss of $5.42 per share if they sold it today. The stock has fallen 15.38% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $24.03.
Bruker shares have an all-time high of $94.27, representing 40.96% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Bruker stock currently has an RSI of 26.13, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
BRKR has a 52-week high of $94.86 and a 52-week low of $53.79.

Why Bruker (BRKR) Shares Are Falling During Thursday's Session

WIIM

Bruker shares are trading lower after the company announced a public offering of 6 million shares of its common stock.

Bruker intends to use the net proceeds from the offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024.

Reported Earlier, Bruker Prices Public Offering Of 6M Shares Of Common Stock

Bruker shares are trading lower after the company announced an underwritten registered public offering of 6 million shares of its common stock.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54022322&amp;newsitemid=20240529283091&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=ab98aa193ce98152d1081babd0957b3e">Bruker Corporation</a> ("Bruker" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bruker intends to use the net proceeds from this offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024. BofA Securities and J.P. Morgan are acting as joint underwriters and book-running managers for the offering.

Offerings

Bruker Announces Public Offering Of 6M Shares Of Common Stock

Bruker Files To Sell 6M Common Shares

Throughout the last three months, 4 analysts have evaluated Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $85.75, a high estimate of $102.00, and a low estimate of $74.00. This upward trend is apparent, with the current average reflecting a 2.08% increase from the previous average price target of $84.00.
<img src="https://www.benzinga.com/files/images/story/2024/1716213638_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Bruker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$77.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bruker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Get to Know Bruker Better</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Bruker: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bruker's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 7.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's ROE stands out, surpassing industry averages. With an impressive ROE of 3.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bruker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.03, Bruker faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Bruker Through Analyst Insights

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $81 to $77.

Stifel Maintains Hold on Bruker, Lowers Price Target to $77

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $95 to $90.

B of A Securities Maintains Buy on Bruker, Lowers Price Target to $90

Bruker Shares Down 2.65%, Co. Began Investor Webinar At 10:00 a.m. ET

Legal

Global

German Federal Patent Court Invalidates European Patent No. 2794928B1 In Germany

NanoString, now a Bruker business, will promptly seek an end to the injunction impacting sales of CosMx SMI products in Germany
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=53977100&amp;newsitemid=20240507563533&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=4c5082ca5ae77a72a52a4eac7e40cb58">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the "928 Patent") in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker's asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString's CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid.
"NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString's CosMx SMI products are invalid. Today's ruling of the German Federal Patent Court is a decisive victory for NanoString and Bruker and a resounding vindication of NanoString's belief from the outset that these cases are without merit. This ruling is also a win for science and enables a re-leveling of the playing field in the research tools industry in Germany," commented Dr. Mark R. Munch, President of the Bruker NANO Group.
Today's decision in Germany follows NanoString's win before the UPC Court of Appeal in Luxembourg in February on a related patent. In that case, the Court overturned a preliminary injunction that had previously been issued by a lower court based on the closely related European Patent 4108782B1 (the "782 Patent"). The UPC Court of Appeal noted in its February ruling that it was likely "that the patent at issue will not prove to be valid," citing concerns about the obviousness of the patent claims based on the prior art. Today's decision of the German Federal Patent Court is in line with that separate court's analysis.
"Today's win is further evidence of the turning of the tide in our favor in these cases," Dr. Munch added. "Bruker expects to build on this significant legal victory and to further fight for scientific freedom."
Following today's win, NanoString will promptly ask the German Higher Regional Court of Munich to permanently lift the injunction impacting NanoString's CosMx products and the scientists who rely on them in Germany. In December 2023, the German Higher Regional Court of Munich cited concerns with the lower Munich Regional Court's May 2023 decision and granted NanoString the right to have the injunction on sales of CosMx products in Germany lifted, subject to payment of a bond. NanoString also expects to have its attorneys' fees and related legal expenses reimbursed in light of today's ruling.

German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win To NanoString, Now A Bruker Business, Will Seek An End To The Injunction Impacting Sales Of CosMx SMI Products In Germany

These 15 large-cap stocks were the worst performers last week. Are they in your portfolio?
<ol>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) shares tumbled 18.2% after it reported first-quarter sales of $88.4 billion, missing the consensus of $89.21 billion, and adjusted EPS of $1.31 <a href="https://www.benzinga.com//node/38549660" target="_blank" rel="noreferrer noopener">missed the consensus of $1.69m and cut FY24 guidance</a>. Several analysts <a href="https://www.benzinga.com//node/38582839" target="_blank" rel="noreferrer noopener">trimmed the price target</a>.</li>
<li>Skyworks Solutions, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares plummeted 16.8% after the company reported&nbsp;Q2&nbsp;financial results and issued&nbsp;Q3&nbsp;revenue&nbsp;guidance&nbsp;with&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38536220" rel="noreferrer noopener">the midpoint below estimates</a>. Several analysts cut the&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38549218" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Starbucks Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) shares decreased 15.2% following worse-than-expected earnings&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38534321" rel="noreferrer noopener">results for the&nbsp;second quarter of FY24</a>. Multiple analysts lowered price targets on the&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38549288" rel="noreferrer noopener">stock&nbsp;following the release</a>.</li>
<li>Super Micro Computer, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are down 14.4% after the company posted mixed&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38555359" rel="noreferrer noopener">third-quarter&nbsp;financial results</a>. Few analysts cut and&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SMCI/analyst-ratings" rel="noreferrer noopener">boosted the price target</a>.</li>
<li>Bruker Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares decreased 13.8% after the company&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38577397" rel="noreferrer noopener">reported&nbsp;Q1&nbsp;revenue miss</a>.</li>
<li>Stellantis N.V.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) shares declined 13.5% after the company reported&nbsp;a&nbsp;12%&nbsp;decrease in first-quarter&nbsp;net revenues and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38515774" rel="noreferrer noopener">a&nbsp;10%&nbsp;reduction in consolidated shipments</a>.&nbsp;</li>
<li>DoorDash, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares declined 13.5% after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38565879" rel="noreferrer noopener">mixed&nbsp;Q1&nbsp;financial results</a>. Most analysts trimmed the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/dash/analyst-ratings" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Centrais Electricas Brasileiras&nbsp;S.A.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBR#NYSE">EBR</a>) shares were down 13.5%.</li>
<li>MicroStrategy Incorporated&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dived 12.7% after the company&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38503135" rel="noreferrer noopener">reported&nbsp;Q1&nbsp;financial results</a>.</li>
<li>GE&nbsp;HealthCare&nbsp;Technologies Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) shares declined 12.5% after it reported&nbsp;first-quarter&nbsp;sales of&nbsp;$4.6 billion, which&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38525477" rel="noreferrer noopener">missed the&nbsp;consensus of&nbsp;$4.8 billion</a>. Some analysts&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/gehc/analyst-ratings" rel="noreferrer noopener">reduced the price target</a>.</li>
<li>The Carlyle Group Inc.&nbsp;(NASDAQ:&nbsp;CG) shares decreased 12.4% after the company reported&nbsp;Q1&nbsp;financial results.</li>
<li>Global Payments Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares were down 11.3% after it reported&nbsp;Q1&nbsp;financial&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38558593" rel="noreferrer noopener">results and issued&nbsp;guidance</a>.</li>
<li>Banco Bilbao Vizcaya Argentaria S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) shares declined 11.3% after reporting first-quarter FY24 results. The company reportedly confirmed its intention to start talks with Sabadell on a potential merger.</li>
<li>CDW Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) shares declined 11.2%&nbsp;after the company reported worse-than-<a target="_blank" href="https://www.benzinga.com//node/38559196" rel="noreferrer noopener">expected&nbsp;Q1&nbsp;financial results</a>. Analysts trimmed&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38559196" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>APA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) shares are down 10.8% after it reported worse-than-expected&nbsp;Q1&nbsp;earnings and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38564165" rel="noreferrer noopener">APA revised FY24&nbsp;guidance</a>.&nbsp;</li>
</ol>
Also Read: <a href="https://www.benzinga.com/markets/equities/24/05/38633878/which-large-cap-stocks-are-winning-this-earnings-season-15-stocks-to-watch-april-28-may-4-2024">Which Large Cap Stocks Are Winning This Earnings Season: 15 Stocks To Watch (April 28-May 4, 2024)</a>
Photo: Shutterstock

Last Week's Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)

<h3>Gainers</h3>
<ul>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares moved upwards by 25.37% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares fell 27.6% to $1.57 during Thursday's regular session. The market value of their outstanding shares is at $155.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) shares fell 17.62% to $5.8. The market value of their outstanding shares is at $217.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 11.26% to $3.55. The company's market cap stands at $172.7 million. The company's, Q1 earnings came out today. </li>
<li>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) stock fell 11.13% to $70.24. The company's market cap stands at $10.2 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 10.97% to $1.34. The company's market cap stands at $46.4 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock declined by 10.84% to $3.0. The market value of their outstanding shares is at $144.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAY

BCAB

ELEV

JAGX

NUWE

OCEA

SNSE

SYRA

TTNP

12 Health Care Stocks Moving In Thursday's Intraday Session

Bruker shares are trading lower after a Q1 revenue miss.

Fiscal Year 2024 Financial&nbsp;Outlook
Bruker&#39;s FY 2024 updated&nbsp;guidance&nbsp;now includes the expected benefits of the Chemspeed acquisition closed in&nbsp;Q1&nbsp;2024, and of the ELITech acquisition, which closed on April 30, 2024. Our updated FY 2024&nbsp;guidance&nbsp;does not include the pending, EPS-dilutive NanoString acquisition, announced by Bruker on April 22, 2024, and expected to close in&nbsp;Q2-24.
Bruker now expects FY 2024 revenues of&nbsp;$3.29&nbsp;to&nbsp;$3.35 billion, up&nbsp;$60 million&nbsp;from our prior&nbsp;guidance&nbsp;of&nbsp;$3.23&nbsp;to&nbsp;$3.29 billion. Bruker&#39;s updated FY 2024 revenue&nbsp;guidance&nbsp;implies&nbsp;11%&nbsp;to&nbsp;13%&nbsp;year-over-year reported revenue growth, up from our prior&nbsp;guidance&nbsp;of&nbsp;9%&nbsp;to&nbsp;11%, and including yoy contributions from:
<ul>
<li>Organic revenue growth of&nbsp;5%&nbsp;to&nbsp;7%, no change from prior&nbsp;guidance</li>
<li>Constant exchange rate (CER) revenue growth of&nbsp;12%&nbsp;to&nbsp;14%, up 400 bps vs. prior&nbsp;guidance, and reflecting all closed acquisitions, including Chemspeed and ELITech</li>
<li>Foreign currency translation headwind of&nbsp;-1%, vs. prior expectation of a&nbsp;+1%&nbsp;tailwind.</li>
</ul>
Bruker now expects FY 2024 non-GAAP EPS of&nbsp;$2.79&nbsp;to&nbsp;$2.84, up 8 cents from our prior&nbsp;guidance&nbsp;of&nbsp;$2.71&nbsp;to&nbsp;$2.76, and excluding the estimated impact of the pending dilutive NanoString acquisition.
Bruker&#39;s updated FY 2024 revenue and non-GAAP EPS&nbsp;guidance&nbsp;is based on foreign currency exchange rates as of March 31, 2024.

Earnings

Guidance

Bruker Updates 2024 Outlook: Now Sees Revenue Of $3.29B-$3.35B (Prior  $3.23B-$3.29B) Vs. $3.282B Est.; Sees Adjusted EPS Of $2.79 To $2.84 (Prior $2.71-$2.76) Vs. $2.71 Est.

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.46 by 15.22 percent. This is a 17.19 percent decrease over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $721.700 million which missed the analyst consensus estimate of $729.879 million by 1.12 percent. This is a 5.31 percent increase over sales of $685.300 million the same period last year.

Earnings Beats

Earnings Misses

Bruker Q1 2024 Adj EPS $0.53 Beats $0.46 Estimate, Sales $721.700M Miss $729.879M Estimate

Bruker shares are trading higher amid strength in life sciences tools stocks following strong earnings from Danaher and strong guidance from Medpace.

Daniel Brennan, an analyst from TD Cowen, maintained the Hold rating on Bruker (BRKR – Research Report). The associated price target remains the sa...

Bruker Corporation: Hold Rating Maintained Amid EPS Target Reduction and Acquisition Uncertainties

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MacroGenics (MGNX – Research Report) and Bruker (BRK...

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Bruker (BRKR)

Bank of America Securities analyst Michael Ryskin has reiterated their bullish stance on BRKR stock, giving a Buy rating on May 17. Michael Ryskin ...

Bruker Corporation: Strong Growth and Strategic Acquisitions Support Buy Rating

Bruker announces offering of common stock

Salesforce, Nutanix, Bruker among premarket losers' pack

Bruker: A Confusing Acquisition Spree

Jefferies analyst Tycho Peterson maintained a Buy rating on Bruker (BRKR – Research Report) today and set a price target of $85.00. The company's s...

Jefferies Keeps Their Buy Rating on Bruker (BRKR)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Business leaders often talk about thinking big. But when it comes to nanotech stocks, the future is all about focusing on the small things.



According to the European Commission, nanotechnology represents a <a href="https://ec.europa.eu/health/scientific_committees/opinions_layman/en/nanotechnologies/l-2/1-introduction.htm#:~:text=Nanotechnology%20refers%20to%20the%20branch,of%20a%20millimetre)%20or%20less.">scientific and engineering discipline</a> that&rsquo;s &ldquo;devoted to designing, producing, and using structures, devices, and systems by manipulating atoms and molecules at nanoscale.&rdquo; Nanoscales refer to having one or more dimensions of the order of 100 nanometers (or 100 millionth of a millimeter).



Stated differently, nanotechnology centers on density; that is, being able to pack various capacities in an extremely small space. According to Grand View Research, this field features enormous potential and applications across various scientific domains, including chemistry, biomedical science, mechanics and materials science.



In terms of hard numbers, the global nanotech market <a href="https://www.grandviewresearch.com/industry-analysis/nanotechnology-market-report">reached a valuation of $3.69 billion in 2022</a>. By 2030, the ecosystem could be worth $36.85 billion, or a compound annual growth rate (CAGR) of 33.1%. With projected expansion like that, it pays to at least consider these nanotech stocks.



<h2>Veeco Instruments (VECO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/semiconductor1600c-300x169.jpg" alt="AI. Circuit board. Technology background. Central Computer Processors CPU concept. Motherboard digital chip. Tech science background. Integrated communication processor. 3D illustration representing semiconductor stocks. Semiconductors Stocks to Sell"><div>Source: Shutterstock</div></div>Based in Plainview, New York, Veeco Instruments (NASDAQ:<a href="https://investorplace.com/stock-quotes/veco-stock-quote/">VECO</a>) falls under the semiconductor sector; specifically, it works in the field of semiconductor equipment and materials. Per its public profile, Veeco focuses on thin film process equipment primarily to develop electronic devices. It&rsquo;s one of the top nanotech stocks thanks to the microscopic precision needed to develop these high-performance semiconductor devices.



To be sure, VECO stock has already enjoyed a robust performance so far this year. However, it&rsquo;s one of the small middle-capitalization plays, making it an intriguing idea for the long haul. One aspect that&rsquo;s impressive is its financial performance. Between the second quarter of 2023 to Q1 2024, the company&rsquo;s average earnings per share reached 46.3 cents. This translated to an earnings surprise of 23.6%.



During the trailing 12 months, Veeco did incur a net loss of $17.25 million or 36 cents per share. However, revenue hit $687.41 million. Overall, for fiscal 2024, covering experts anticipate a recovery, with EPS possibly rising 7.1% to hit $1.81. Further, sales could increase by 8% to hit $719.47 million. Therefore, VECO makes a solid case for nanotech stocks to consider.



<h2>Bruker (BRKR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/brkr-1600-300x169.jpg" alt="Bruker sign and logo at office of manufacturer of scientific instruments for molecular and materials research company"><div>Source: Michael Vi / Shutterstock.com</div></div>Headquartered in Billerica, Massachusetts, Bruker (NASDAQ:<a href="https://investorplace.com/stock-quotes/brkr-stock-quote/">BRKR</a>) falls under the healthcare sector, specifically dealing with medical devices. <a href="https://stockanalysis.com/stocks/brkr/company/">Per its corporate profile</a>, Bruker with its subsidiaries develops, manufactures and distributes scientific instruments, along with analytical and diagnostic solutions. Many of its tools &ndash; such as electronic microscopes &ndash; are vital for nanotechnology research and development.



Financially, BRKR stock makes a case for top nanotech stocks thanks to its consistency of performance. Between Q2 2023 to Q1 2024, the company&rsquo;s average EPS reached 64.3 cents. This translated to an average earnings surprise of 13.63%. Notably, the company beat all of the past four of its bottom-line profitability targets.



During the TTM period, Bruker posted net income of $401.6 million, translating to earnings of $2.73 per share. Revenue during this cycle reached $3 billion. For fiscal 2024, analysts anticipate on average a slight dip in EPS to $2.66. However, revenue could see a 14% rise from the prior year to hit $3.38 billion.



In fiscal 2025, EPS could move up 18% to land at $3.14. On the top line, revenue may see an 8.6% lift to reach $3.67 billion. All in all, BRKR makes another solid case for nanotech stocks.



<h2>Luna Innovations (LUNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/shutterstock_1926453779-300x169.png" alt="top Tech stocks to watch : Double exposure of man's hands holding and using a phone and financial graph drawing. tech stocks"><div>Source: Peshkova / Shutterstock</div></div>If you want to dive into the extremely speculative side of the sector, consider Luna Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/luna-stock-quote/">LUNA</a>). Falling under the technology sphere, Luna is involved in the scientific and technical instruments industry. <a href="https://stockanalysis.com/stocks/luna/company/">According to its profile</a>, Luna provides fiber optic tests, measurements and control products worldwide. Its advanced optical solutions feature relevance for entities seeking nanoscale measurements and monitoring.



To be fair, Luna&rsquo;s speculative nature shows when it comes to its earnings performances. It hasn&rsquo;t been hit or miss. Rather, it&rsquo;s been more miss or not miss. However, the company does enjoy generally positive analyst coverage that goes back to November of last year. The latest call from Needham&rsquo;s Alex Henderson is a &ldquo;buy&rdquo; with an $8 price target, which is massive.



During the TTM period, Luna posted a net loss of $1.12 million, or three cents per share. Revenue in the cycle landed at $116.61 million. Now, due to <a href="https://cardinalnews.org/2024/04/19/roanoke-based-luna-innovations-says-more-financial-statements-are-unreliable/">accounting errors</a>, some of the numbers that have been broadcasted are not fully reliable. Obviously, that&rsquo;s a concern.



Still, if you want to take the risk, analysts see fiscal 2024 revenue to rise to $165.24 million. That&rsquo;s a sizable leap from <a href="https://www.gurufocus.com/stock/LUNA/financials?search=luna">prior top-line performances</a>, making it a high-leverage gamble among nanotech stocks.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/rags-to-riches-3-nanotech-stocks-that-could-make-early-investors-rich/">Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Rags to Riches: 3 Nanotech Stocks That Could Make Early Investors Rich

Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Bruker Corp

top performing BRKR trades